Claris Biotherapeutics
Claris Biotherapeutics: Innovating noninvasive, topical treatments for corneal healing.
- 6
- Private company
- Half Moon Bay, CA, USUnited States
Claris Biotherapeutics: Innovating noninvasive, topical treatments for corneal healing.
clarisbio.comCrawled Sep 24, 2026
Claris Bio is dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist.
Claris Biotherapeutics presents clinical proof-of-concept data for **CSB-001** in treating **limbal stem cell deficiency**. In the study, **41% of treated eyes** showed a gain of **≥15 letters** in vision, compared to **0%** in the non-treatment group. Additionally, **55% of treated eyes** achieved a gain of **≥10 letters**, versus **5%** in the control arm.
Oct 2026GlobeNewswireNews article
Claris Biotherapeutics presents oral research at the **American Academy of Ophthalmology (AAO) 2026 Annual Meeting** and the **Eyecelerator @ AAO** event. The company highlights late-stage advancements in ophthalmic therapies, focusing on clinical data and pipeline progress. Presentations cover key projects aimed at treating eye diseases, reinforcing its position in the biopharmaceutical sector.
Sep 2026GlobeNewswireNews article
Claris Bio moves its corporate headquarters to San Francisco, placing it in a major life sciences and biotech innovation cluster. The company is progressing its lead asset, **CSB-001**, toward late-stage trials for **limbal stem cell deficiency (LSCD)**—a rare eye disorder.
Sep 2026BioSpaceNews article
Claris Bio raises **$118 million in Series B funding** to develop treatments for rare corneal diseases. The company, backed by **Novo Holdings**, targets unmet medical needs in eye care, positioning itself to address a potentially significant market. Early-stage research focuses on novel therapies for conditions affecting the cornea, a critical component of vision.
Jul 2026Fierce BiotechNews article